Significance of serum tumor markers in patients with carcinoma of the ovary.
A comparison of preoperative serum tumor markers (lactate dehydrogenase, lactate dehydrogenase isoenzymes, alpha-hydroxybutyrate dehydrogenase, alkaline phosphatase, aldolase, leucine aminopeptidase, cholinesterase, erythrocyte sedimentation reaction, carcinoembryonic antigen, alpha-fetoprotein, and beta 2-microglobulin) was made in 76 patients with ovarian or uterine cancer. Sixty-six patients with benign ovarian tumor served as control subjects. From analysis of each tumor marker the greatest positive results were obtained with the markers beta 2-microglobulin (57.1%), lactate dehydrogenase (53.1%), and hydroxybutyrate dehydrogenase (46.2%) for patients with carcinoma of the ovary. The use of these marker combinations in all ovarian cancer patients resulted in a marked increase of the positive rate from 57.1 to 85.2%. In stage I cases, the positive rate increased from 40.6 to 63.6%.
D000230:Adenocarcinoma / Q000097:blood* / Q000601:surgery; D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D000626:Aminopeptidases / Q000097:blood; D001799:Blood Sedimentation; D002272:Carcinoembryonic Antigen / Q000032:analysis; D003536:Cystadenocarcinoma / Q000097:blood* / Q000601:surgery; D005260:Female; D006801:Humans; D006884:Hydroxybutyrate Dehydrogenase / Q000097:blood; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood* / Q000601:surgery; D011379:Prognosis; D011863:Radioimmunoassay; D014594:Uterine Neoplasms / Q000097:blood* / Q000601:surgery; D000509:alpha-Fetoproteins / Q000032:analysis; D001613:beta 2-Microglobulin / Q000032:analysis
D002272:Carcinoembryonic Antigen; D000509:alpha-Fetoproteins; D001613:beta 2-Microglobulin; D007770:L-Lactate Dehydrogenase; D006884:Hydroxybutyrate Dehydrogenase; D000469:Alkaline Phosphatase; D000626:Aminopeptidases